title: Quantitative tissue and gene-specific differences and developmental changes in Nat1, Nat2, and Nat3 mRNA expression in the rat.
abstract: Human N-acetyltransferase 1 (NAT1) and 2 (NAT2) are important phase II enzymes involved in the biotransformation of xenobiotics. In toxicity and carcinogenicity studies, functional polymorphism of rat N-acetyltransferase is considered a model for similar human variability. To accurately quantitate expression of the three rat N-acetyltransferases, we developed sensitive, specific assays for Nat1, Nat2, and Nat3 mRNAs. In male F344 rats, tissue-specific expression varied over a limited range for both Nat1 (approximately 19-fold) and Nat2 (approximately 30-fold), with the highest expression of both genes in colon. Expression of Nat3 mRNA was at least 2 to 3 orders of magnitude less than that of Nat1 or Nat2. Comparison of Nat1 and Nat2 mRNA expression in bladder, colon, liver, and lung of male and female F344 rats detected no significant gender-specific difference. In Sprague-Dawley and F344 rats ranging in age from neonate to mature adult, colon showed a >10-fold increase in Nat2 during the first postnatal month that did not correlate with changes in Nat1. In contrast, Nat2 showed no developmental change in Sprague-Dawley or F344 liver as Nat1 increased modestly. These measures of rat Nat expression confirm that Nat3 expression is negligible and that Nat1 and Nat2 are the primary determinants of arylamine acetylation activity in all tissues tested. The findings demonstrate differential tissue-specific and developmental regulation of the rat Nat1 and Nat2 genes and contribute to more complete understanding of tissue-, gender-, and development-specific expression patterns of the cognate N-acetyltransferase genes of humans and other species.
authors.affiliation: Department of Pharmacology and Toxicology, University of Louisville School of Medicine, Louisville, KY 40292, USA.
authors.forename: David F
authors.initials: DF
authors.lastname: Barker
authors.forename: Jason M
authors.initials: JM
authors.lastname: Walraven
authors.forename: Elizabeth H
authors.initials: EH
authors.lastname: Ristagno
authors.forename: Mark A
authors.initials: MA
authors.lastname: Doll
authors.forename: J Christopher
authors.initials: JC
authors.lastname: States
authors.forename: David W
authors.initials: DW
authors.lastname: Hein
mesh_terms: D000375:Aging / Q000235:genetics; D000818:Animals; D001191:Arylamine N-Acetyltransferase / Q000235:genetics*; D003106:Colon / Q000254:growth & development / Q000378:metabolism; D005260:Female; D018507:Gene Expression Regulation, Developmental; D015971:Gene Expression Regulation, Enzymologic; D007527:Isoenzymes / Q000235:genetics*; D008099:Liver / Q000254:growth & development / Q000378:metabolism; D008297:Male; D009928:Organ Specificity; D016133:Polymerase Chain Reaction; D051381:Rats; D011916:Rats, Inbred F344; D017207:Rats, Sprague-Dawley; D012727:Sex Characteristics
chemical_list: D007527:Isoenzymes; D001191:Arylamine N-Acetyltransferase; C089384:N-acetyltransferase 1
references.citation: Toxicol Lett. 2000 Mar 15;112-113:349-56
references.pmid: 10720751
references.citation: Biochim Biophys Acta. 1988 Aug 3;948(1):37-66
references.pmid: 3293663
references.citation: Drug Metab Dispos. 2007 May;35(5):721-7
references.pmid: 17287389
references.citation: Chem Biol Interact. 2003 Mar 6;145(1):77-87
references.pmid: 12606156
references.citation: Drug Metab Dispos. 1991 Sep-Oct;19(5):933-7
references.pmid: 1686239
references.citation: Mutat Res. 1997 May 12;376(1-2):101-6
references.pmid: 9202744
references.citation: Drug Metab Rev. 2005;37(3):511-64
references.pmid: 16257833
references.citation: Cancer Epidemiol Biomarkers Prev. 2000 Jan;9(1):29-42
references.pmid: 10667461
references.citation: Drug Metab Dispos. 2000 Feb;28(2):139-46
references.pmid: 10640510
references.citation: Biochem Pharmacol. 2008 Apr 1;75(7):1550-60
references.pmid: 18280460
references.citation: Biochem J. 1994 Sep 1;302 ( Pt 2):347-53
references.pmid: 7545952
references.citation: Mol Carcinog. 2006 Apr;45(4):230-8
references.pmid: 16482518
references.citation: Adv Pharmacol. 1994;27:401-30
references.pmid: 8068562
references.citation: Drug Metab Dispos. 2007 Jul;35(7):1064-70
references.pmid: 17403913
references.citation: Biochem J. 2003 Nov 1;375(Pt 3):593-602
references.pmid: 12904181
references.citation: Drug Metab Dispos. 1998 May;26(5):502-5
references.pmid: 9571233
references.citation: Toxicol Appl Pharmacol. 1997 Feb;142(2):360-6
references.pmid: 9070359
references.citation: Toxicol Sci. 2003 Jun;73(2):279-86
references.pmid: 12700401
references.citation: Toxicol Sci. 2007 Oct;99(2):413-21
references.pmid: 17567587
references.citation: Eur J Biochem. 1995 Feb 15;228(1):129-37
references.pmid: 7882993
references.citation: Mol Pharmacol. 2003 Jul;64(1):170-9
references.pmid: 12815173
references.citation: J Pharmacol Exp Ther. 1991 Jul 1;258(1):232-6
references.pmid: 2072298
references.citation: J Pharmacol Exp Ther. 2006 Oct;319(1):369-75
references.pmid: 16829624
references.citation: J Pharmacol Exp Ther. 2006 Nov;319(2):724-8
references.pmid: 16857729
references.citation: Drug Metab Dispos. 2007 Sep;35(9):1649-56
references.pmid: 17591675